The increasing demand for asthma treatment is largely driven by the rising number of asthma cases. Factors such as increased smoking and air pollution are impairing lung function and contributing to ...

Corp. v. Breckenridge Pharm ... Manual of Patent Examining Procedure § 1490(VI)(A); see also Boehringer Ingelheim Int’l GmbH v. Barr Labs., Inc., 592 F.3d 1340 (Fed. Cir.

Progressive pulmonary fibrosis (PPF) is an increasingly recognised condition, defined in 2022 to address the progression of ...

Hosted by Boehringer Ingelheim, the ‘CRM Summit’, an expert engagement forum, and the ‘IMETA CRM Discussions for EXperts (MEDEX CRM)’, a scientific expert meeting, brought together healthcare ...

Find out how this could enhance access to quality healthcare, with an emphasis on mental health services for vulnerable populations.

*Based on data released by the Federal Election Commission on October 01, 2024 except for independent expenditure and communication cost, contributions to federal candidates, and contributions from ...

The need for antiemetic drugs, which help prevent or relieve nausea and vomiting, is growing for several reasons. A key factor is the rising incidence of conditions and treatments that cause these ...

Boehringer Ingelheim partners with the WHO Foundation to financially support WHO’s Fourteenth General Programme of Work (2025 to 2028). Credit: PeopleImages.com – Yuri A/Shutterstock. Boehringer ...

The Progressive Fibrosing Interstitial Lung Disease (PF-ILD) market is currently valued at USD 4,742.2 Million in 2023 and is ...

Denmark's Zealand Pharma and German partner Boehringer Ingelheim have won the U.S. Food and Drug Administration's Breakthrough Therapy for the review of their experimental weight-loss drug for the ...